Create issue ticket

12 Possible Causes for Thickening of the Mitral Valve Leaflets, Treatment with Enzyme Replacement Therapy

  • Mucopolysaccharidosis

    Available treatment includes enzyme replacement therapy, the incorporation of the missing enzyme into the body through the veins.[nxgenmdx.com] Management and treatment Before enzyme replacement therapy (ERT) with galsulfase (Naglazyme ), clinical management was limited to supportive care and hematopoietic stem cell[orpha.net] (enzyme replacement therapy).[ncbi.nlm.nih.gov]

  • Mucopolysaccharidosis 1 H-S

    Differential diagnosis Other forms of MPS I ; Hunter Syndrome ; other mucopolysaccharidoses Treatment Enzyme replacement therapy with iduronidase ; surgery Prognosis Life[en.wikipedia.org] Progressive thickening and stiffening of the valve leaflets can lead to mitral and aortic regurgitation, which may become hemodynamically significant in the later stages of[ncbi.nlm.nih.gov] [ edit ] Enzyme replacement therapy adds a working form of the missing enzyme to the body.[en.wikibooks.org]

  • Fabry Disease

    […] with enzyme replacement therapy, Nephrology Dialysis Transplantation, Volume 23, Issue 5, May 2008, Pages 1600–1607, Download citation file: Ris (Zotero) EndNote BibTex Medlars[ndt.oxfordjournals.org] […] without significant luminal occlusion. c Section through the mitral valve apparatus demonstrating mild mitral valve leaflet thickening and ballooning of the anterior and[doi.org] Their detection is important for early diagnosis and institution of treatment with enzyme replacement therapy, which prevents late complications reducing morbidity and mortality[ncbi.nlm.nih.gov]

  • Mucopolysaccharidosis 2

    Enzyme replacement therapy with recombinant iduronate-2-sulphatase (idursulfase), however, has now been introduced.[ingentaconnect.com] Fig. 1 Subcostal echocardiographic view showing anterior (arrowhead) and posterior mitral valve thickening with subvalvular involvement (asterisk).[karger.com] The treatment is termed enzyme replacement therapy (ERT) using an IV – infused enzyme (Elaprase).[medicinenet.com]

  • Mucopolysaccharidosis 1

    Available treatment includes enzyme replacement therapy, the incorporation of the missing enzyme into the body through the veins.[nxgenmdx.com] Progressive thickening and stiffening of the valve leaflets can lead to mitral and aortic regurgitation, which may become hemodynamically significant in the later stages of[ncbi.nlm.nih.gov] Treatment with enzyme replacement therapy is available.[neurology.testcatalog.org]

  • Mucopolysaccharidosis 4

    In 2014, Vimizin was approved by the FDA as a enzyme replacement therapy for MPS IVA. There is no treatment for MPS IVB.[mpssociety.org] […] minimal to mild thickened mitral and/or aortic valve leaflets.[journals.plos.org] Enzyme replacement therapy with laronidase aims to replace the missing enzyme; however, given its high cost, it is essential to assess how effective and safe this treatment[cochrane.org]

  • Mucopolysaccharidosis 4A

    In 2014, Vimizin was approved by the FDA as a enzyme replacement therapy for MPS IVA. There is no treatment for MPS IVB.[mpssociety.org] Valvular involvement, with thickening and stiffening of the valve leaflets, commonly leads to mitral and aortic regurgitation and/or stenosis [ 24 ].[link.springer.com] Management and treatment Before enzyme replacement therapy (ERT) with galsulfase (Naglazyme ), clinical management was limited to supportive care and hematopoietic stem cell[rarediseases.info.nih.gov]

  • Arrhythmogenic Right Ventricular Dysplasia

    Alglucosidase alfa (Myozyme ) is a recombinant, intravenous enzyme replacement therapy that is now funded by PHARMAC for use in IPD in New Zealand.[starship.org.nz] Persistent mitral regurgitation leads to thickening of the mitral valve leaflets, and, at times, it is difficult to distinguish this thickening from other causes of mitral[transplantbuddies.org] The effectiveness of treatment is greatly influenced by age at diagnosis thus if IPD is suspected, the metabolic service should be notified for urgent review and initiation[starship.org.nz]

  • Myocardial Fibrosis

    View Article PubMed Google Scholar Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C: Clinical benefit of enzyme replacement therapy in Fabry disease.[bmccardiovascdisord.biomedcentral.com] leaflets and in the mitral subvalvular apparatus, causing thickening, retraction, and stiffening of valves and resulting in incomplete leaflet coaptation and valve regurgitation[doi.org] (B) Mitral valve leaflet with spontaneous mitral valvulopathy from a Sprague Dawley rat.[doi.org]

  • Mucopolysaccharidosis 1S

    Continued Treatment Enzyme replacement therapy (ERT) uses a drug called laronidase (Aldurazyme), a man-made version of the missing protein.[webmd.com] Progressive thickening and stiffening of the valve leaflets can lead to mitral and aortic regurgitation, which may become hemodynamically significant in the later stages of[ncbi.nlm.nih.gov] Treatment options include enzyme replacement therapy and hematopoietic stem cell transplantation.[jcor.in]

Further symptoms